Mail News

Modalis Therapeutics Corporation provides the latest IR information via email.
Our “IR Email Subscription Service” delivers updates on various disclosures, website updates, and other IR-related information. This service is available free of charge to anyone with an email address.

<Disclaimer>

While we make every effort to ensure the accuracy of the content in our IR emails, we assume no responsibility for any errors in the published information or any problems arising from data downloads or other related issues.
Please note that if we are unable to send an email to your registered email address, we may delete that email address from our records. Please also be aware that we may suspend or discontinue this email service without prior notice.

<Important Notes>

We take necessary measures to protect the email address you have registered against leakage, loss, destruction, and unauthorized access, use, or alteration.
We will not use the email address you have registered for any purpose other than email distribution.
We will not disclose the email address you have registered to third parties without your consent, except when required by law and we deem the reason for the request to be valid.
The sender address used by our company to send emails is for sending purposes only. Please note that we are unable to respond to replies or inquiries sent via email.

＜How to Register＞

After submitting the registration form, a confirmation email will be sent to your registered email address.
Click the link in the email.
On the confirmation page, click the 「確認」(“Confirm”) button. Your registration will then be completed.
Please note that notification emails will be sent in Japanese. For information in English, please visit the MODALIS website.